Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GSP TRADE STATUS: LINKAGE TO INTELLECTUAL PROPERTY PROTECTION

This article was originally published in The Tan Sheet

Executive Summary

GSP TRADE STATUS: LINKAGE TO INTELLECTUAL PROPERTY PROTECTION levels in developing nations will be the subject of a June 20 hearing of Sen. Max Baucus' (D-Mont.) International Trade Subcommittee, A bill (S 2041) introduced April 21 by Sen. Frank Lautenberg (D-N.J.) and another (S 2173) by Sen. William Ruth (R- Del.) on June 9 both contain passages linking duty-free privileges allowed under the Generalized System of Preferences (GSP) to developing nations' implementation of the Agreement on Trade- Related Aspects of Intellectual Property Rights. TRIPS was negotiated as part of the Uruguay Round of the General Agreement on Tariffs and Trade.

You may also be interested in...



Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

In Brief

Combe sells most of its OTC brands

People In Brief

Perrigo promotes in pricing, planning

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS082911

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel